David M. Gershenson
Houston gynaecologic oncologist who defined low-grade serous ovarian cancer as a distinct disease and led GOG 281, the trial that showed the MEK inhibitor trametinib works better than standard treatments for it.
Overview
David Gershenson is a gynaecologic oncologist at MD Anderson Cancer Center whose work established low-grade serous carcinoma of the ovary as a separate, relatively chemotherapy-resistant disease. He was first author of the 2017 Journal of Clinical Oncology study of hormonal maintenance therapy after primary treatment and of the 2022 Lancet report of GOG 281/LOGS, in which trametinib lengthened progression-free survival compared with standard-of-care options in recurrent low-grade serous carcinoma. He has also led studies of rare ovarian germ cell and sex cord-stromal tumours.
MEK inhibition is a standard option for recurrent low-grade serous ovarian cancer, and the trial validated the MAPK pathway as the disease's therapeutic target, now extended by avutometinib-defactinib.
Letrozole maintenance after first-line therapy is now common practice and guideline-supported for low-grade serous ovarian cancer, and the randomised NRG-GY019 trial is testing letrozole alone.
Similar pages
not linked directly; found by shared links- PersonSusana Banerjee
Shares Low-grade serous ovarian cancer, Ovarian cancer and the tags ovarian, gynaecological, trialist.
- PersonShannon N. Westin
Shares MD Anderson Cancer Center, Ovarian cancer and the tags gynaecological, trialist.
- PersonMansoor Raza Mirza
Shares Ovarian cancer and the tags ovarian, trialist.
- PersonAmanda Nickles Fader
Shares the tags gynaecological, trialist.
- PersonKrishnansu S. Tewari
Shares the tags gynaecological, trialist.
- PersonKathleen N. Moore
Shares Ovarian cancer and the tags ovarian, trialist.
- TrialA Study of Avutometinib + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer in Japanese Patients
- PersonAna Oaknin
Shares the tags gynaecological, trialist.